Present at the Revolution: Transformation of Technical Identity for a Large Incumbent Pharmaceutical Firm After the Biotechnological Breakthrough
This paper is a case study of the transformation in research methods which occurred in a large U.S. pharmaceutical firm as a result of the biotech revolution. This transformation is inconsistent with the hypothesis that technological revolutions make existing firms obsolete and consistent with our wealth-maximization hypothesis that valuable assets (like delivery know-how) will not be wasted if technological change in part of the organization is necessary to remain competitiveness. While the transformation was achieved through a various methods, the primary route was hiring new personnel who had the new technology and incorporating them into the existing structure. While the technological transformation has been profound, biotechnology applications in this large incumbent firm are more likely to be combined with other techno- logies than in the new biotechnology firms (NBFs) which use biotechnology for both discovery and production of new therapeutic entities. This difference in emphasis may result in value-enhancing synergies because of the related knowledge which makes for more effective applications of the new technologies, but it could retard full adoption of biotechnology. It appears that this firm was somewhat slower than the dedicated biotech firms to adopt the new techno- ogy, but once the decision was made to transform the technological identity of the firm massive resources were provided to recruit the human capital required to make it happen. The incumbent firms were slow to adopt biotechnology, but made great strides in the 1980s in increasing their share of all commercial ties to the star scientists as well as their share of patents.
|Date of creation:||Aug 1995|
|Publication status:||published as Research Policy 26 (1997) 429-446|
|Contact details of provider:|| Postal: National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.|
Web page: http://www.nber.org
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Reinganum, Jennifer F, 1983.
"Uncertain Innovation and the Persistence of Monopoly,"
American Economic Review,
American Economic Association, vol. 73(4), pages 741-748, September.
- Reinganum, Jennifer R., 1982. "Uncertain Innovation and the Persistence of Monopoly," Working Papers 431, California Institute of Technology, Division of the Humanities and Social Sciences.
- Wooldridge, Jeffrey M., 1991. "On the application of robust, regression- based diagnostics to models of conditional means and conditional variances," Journal of Econometrics, Elsevier, vol. 47(1), pages 5-46, January.
- Comanor, William S, 1986. "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 24(3), pages 1178-1217, September.
- Lynne G. Zucker & Michael R. Darby & Jeff Armstrong, 1994. "Intellectual Capital and the Firm: The Technology of Geographically Localized Knowledge Spillovers," NBER Working Papers 4946, National Bureau of Economic Research, Inc.
- Elise Brezis & Paul Krugman & Daniel Tsiddon, 1991. "Leapfrogging: A Theory of Cycles in National Technological Leadership," NBER Working Papers 3886, National Bureau of Economic Research, Inc.
- Reinganum, Jennifer F., 1989. "The timing of innovation: Research, development, and diffusion," Handbook of Industrial Organization,in: R. Schmalensee & R. Willig (ed.), Handbook of Industrial Organization, edition 1, volume 1, chapter 14, pages 849-908 Elsevier.
- Zucker, Lynne G. & Darby, Michael R., 1994. "The Organization of Biotechnology Science and Its Commercialization in Japan," Institute for Social Science Research, Working Paper Series qt9qf459t4, Institute for Social Science Research, UCLA.
- Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
- Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July. Full references (including those not matched with items on IDEAS)